Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-invasive Bladder Cancer × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 31 Carcinoma, Non-Small-Cell Lung 20 Melanoma 18 Squamous Cell Carcinoma of Head and Neck 15 Colorectal Neoplasms 15 Urinary Bladder Neoplasms 10 Prostatic Neoplasms 9 Lung Neoplasms 9 Breast Neoplasms 9 Small Cell Lung Carcinoma 8 Liver Neoplasms 8 Carcinoma, Renal Cell 8 Neoplasms 7 Diabetes Mellitus, Insulin-Dependent, 12 7 Biliary Tract Neoplasms 7 Pancreatic Neoplasms 6 Head and Neck Neoplasms 6 Cholangiocarcinoma 6 Ovarian Neoplasms 5 Uterine Cervical Neoplasms 4 Neoplasm Metastasis 4 Mesothelioma, Malignant 4 Fallopian Tube Neoplasms 4 Adenocarcinoma Of Esophagus 4 Stomach Neoplasms 3 Mesothelioma 3 Kidney Neoplasms 3 Carcinoma, Transitional Cell 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2

Interventions

tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Magnetic Resonance Spectroscopy 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡